July 3, 2018
Medical robotics company Neural Analytics Inc. announced that it received CE Mark for its NeuralBot System, a robotic assistance technology which automatically adjusts orientation and position of its ultrasound products under the guidance of a healthcare professional. The system has also received 510(k) clearance from the U.S. Food and Drug Administration (FDA). When used with its previously cleared Lucid M1 Transcranial Doppler Ultrasound System, it can assist clinicians to non-invasively monitor a patient’s brain blood flow characteristics and can provide information to diagnose a variety of neurological disorders.
“This technology allows us to look inside the brain, evaluate blood flow characteristics and track emboli in patients. It provides us with critical information on brain health in real-time to help us diagnose neurological disorders, prior to the need for additional, more invasive testing,” said Prof. Claudio Baracchini, M.D., FESO, director of the Stroke Unit and Neurosonology Lab at the University of Padua (Italy) and president of the European Society of Neurosonology and Cerebral Hemodynamics (ESNCH).
In April, at the 23rd ESNCH Meeting in Prague, Neural Analytics presented research data that demonstrated there was no statistical difference between ultrasound blood flow data collected with its NeuralBot System or data collected manually by an expert technician with its traditional ultrasound platform.(5)